Asunaprevir阿舒瑞韦,630420-16-5

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Asunaprevir

CAS No. : 630420-16-5

MCE 国际站：Asunaprevir

产品活性：Asunaprevir (BMS-650032) 是一种有效的，具有口服活性的 hepatitis C virus (HCV) NS3 protease 抑制剂，IC₅₀ 值为 0.2 nM-3.5 nM。Asunaprevir 抑制 SARS-CoV-2 3CL^pro 活性。

研究领域：Anti-infection | Metabolic Enzyme/Protease

作用靶点：HCV | HCV Protease | SARS-CoV

In Vitro: In multiple experiments, populations of resistant colonies are markedly reduced when cells are treated with a combination of DCV and Asunaprevir. Asunaprevir (ASV) inhibits the NS3 proteolytic activity of genotype 1a (H77 strain) and genotype 1b (J4L6S strain), with IC₅₀s of 0.7 and 0.3 nM, respectively. The EC₅₀s of ASV against replicons encoding the NS3 protease domains representing genotypes 1a, 1b, and 4a, range from 1.2 to 4.0 nM. Replicon cells are maintained under selective pressure with asunaprevir at concentrations of 10 and 30 times the EC₅₀ values (50 or 150 nM final concentrations, respectively). For genotype 1b resistance selection, replicon cells are maintained in the presence of asunaprevir at 10 or 30 times the EC₅₀ values (30 or 90 nM final concentrations, respectively). Asunaprevir, administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.

In Vivo: Asunaprevir (ASV, 3-15 mg/kg, p.o.) displays a hepatotropic disposition (liver-to-plasma ratios ranging from 40- to 359-fold across species) in several animal species. Twenty-four hours postdose, liver exposures across all species tested are ≥110-fold above the inhibitor EC₅₀ observed with HCV genotype-1 replicons.

相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Antiviral Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Hepatitis C Virus Compound Library | Targeted Diversity Library | Chloroquine | Dexamethasone | Resiquimod | Remdesivir | Molnupiravir | Thapsigargin | Imatinib | Hydroxychloroquine sulfate | Nirmatrelvir | Aloxistatin | ALC-0315 | Favipiravir | Imiquimod | Brequinar | Ivermectin | Camostat mesylate | Auranofin | Honokiol | EIDD-1931 | Deferiprone | Ribavirin | U18666A | AG-1478 | Ritonavir | Simeprevir | Emodin | GS-443902 trisodium | GRL0617

热门产品线：重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物 | 寡核苷酸

Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds | Oligonucleotides

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。